Validation of 4-[18F]-ADAM as a SERT imaging agent using micro-PET and autoradiography

Hsing, Kuo; Huang, Wen Sheng; Kuo, Yu Yeh; Peng, Chi-Jiun; Liou, Nien Hsien; Liu, Ru‐Shi; Hwang, Jeng Jong; Liu, Jiang Chuan; Chen, Haw Jan; Shiue, Chyng‐Yann

doi:10.1016/j.neuroimage.2008.12.060

Cited by 39 publications

(37 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A cylinder calibration method was used to convert the image units from cps per voxel (cps/voxel) to nCi per cm3 (nCi/cm3). Finally, the CT scan was performed by the same machine[17], [18].…”

Section: Methodsmentioning

confidence: 99%

Manipulation Therapy Prior to Diagnosis Induced Primary Osteosarcoma Metastasis—From Clinical to Basic Research

Wang

Chen

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

Osteosarcoma (OS) patients who suffer manipulation therapy (MT) prior to diagnosis resulted in poor prognosis with increasing metastasis or recurrence rate. The aim of the study is to establish an in vivo model to identify the effects of MT on OS. The enrolled 235 OS patients were followed up in this study. In vivo nude mice model with tibia injection of GFP-labeled human OS cells were randomly allocated into MT(+) that with repeated massage on tumor site twice a week and no treatment as MT(−) group. The five-year survival, metastasis and recurrence rates were recorded in clinical subjects. X-ray plainfilm, micro-PET/CT scan, histopathology, serum metalloproteinase 2 (MMP2), metalloproteinase 9 (MMP9) level and human kinase domain insert receptor (KDR) pattern were assayed in mice model. The results showed that patient with MT decreased 5-year survival and higher recurrence or metastasis rate. Compatible with clinical findings, the decreased body weight (30.5±0.65 g) and an increased tumor volume (8.3±1.18 mm3) in MT(+) mice were observed. The increasing signal intensity over lymph node region of hind limb by micro-PET/CT and the tumor cells were detected in lung and bilateral lymph nodes only in MT(+) group. MMP2 (214±9.8 ng/ml) and MMP9 (25.5±1.81 ng/ml) were higher in MT(+) group than in MT(−) group (165±7.8 ng/ml and 16.9±1.40 ng/ml, individually) as well as KDR expression. Taking clinical observations and in vivo evidence together, MT treatment leads to poor prognosis of primary osteosarcoma; physicians should pay more attention on patients who seek MT before diagnosis.

show abstract

Section: Methodsmentioning

confidence: 99%

Manipulation Therapy Prior to Diagnosis Induced Primary Osteosarcoma Metastasis—From Clinical to Basic Research

Wang

Chen

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Subsequently, the dried sections were exposed overnight to an imaging plate (BAS SR2040, 20 × 40 cm 2 ; Fujifilm, Tokyo, Japan). The imaging plate was then scanned with a phosphor image reader (FLA-5100; Fujifilm, Tokyo, Japan), and the obtained images were analysed using Multi Gauge 3.0 software (Fujifilm, Tokyo, Japan) to calculate the striatal specific uptake ratio (SUr), which is defined as (PSL striatum − PSL cerebellum )/PSL cerebellum [41], where PSL is the photostimulated-luminescence intensity [42, 43]. Five consecutive brain sections from each animal were used to determine the target PSL.…”

Section: Methodsmentioning

confidence: 99%

Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson’s disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging

et al. 2017

View full text Add to dashboard Cite

18F-9-Fluoropropyl-(+)-dihydrotetrabenazine [18F-FP-(+)-DTBZ] positron emission tomography (PET) has been shown to detect dopaminergic neuron loss associated with Parkinson’s disease (PD) in human and neurotoxin-induced animal models. A polyphenol compound, magnolol, was recently proposed as having a potentially restorative effect in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- or 6-hydroxydopamine-treated animal models. In this study, 18F-FP-(+)-DTBZ PET was used to determine the therapeutic efficacy of magnolol in an MPTP–PD mouse model that was prepared by giving an intraperitoneally (i.p.) daily dose of 25 mg/kg MPTP to male C57BL/6 mice for 5 consecutive days. Twenty-minute static 18F-FP-(+)-DTBZ PET scans were performed before MPTP treatment and 5 days after the termination of MPTP treatment to set up the baseline control. Half of the MPTP-treated mice then received a daily dose of magnolol (10 mg/kg dissolved in corn oil, i.p.) for 6 days. 18F-FP-(+)-DTBZ PET imaging was performed the day after the final treatment. All 18F-FP-(+)-DTBZ PET images were analysed and the specific uptake ratio (SUr) was calculated. Ex vivo autoradiography (ARG) and corresponding immunohistochemistry (IHC) studies were conducted to confirm the distribution of dopaminergic terminals in the striatum. The striatal SUr ratios of 18F-FP-(+)-DTBZ PET images for the Sham, the MPTP, and the MPTP + Magnolol-treated groups were 1.25 ± 0.05, 0.75 ± 0.06, and 1.00 ± 0.11, respectively (n = 4 for each group). The ex vivo 18F-FP-(+)-DTBZ ARG and IHC results correlated favourably with the PET imaging results. 18F-FP-(+)-DTBZ PET imaging suggested that magnolol post-treatment may reverse the neuronal damage in the MPTP-lesioned PD mice. In vivo imaging of the striatal vesicular monoamine transporter type 2 (VMAT2) distribution using 18F-FP-(+)-DTBZ animal PET is a useful method to evaluate the efficacy of therapeutic drugs i.e., magnolol, for the management of PD.

show abstract

“…The noninvasive nature of these two platforms enables their use in preclinical animal studies and human clinical studies. In contrast, autoradiography imaging [18][19][20][21] is an ex vivo technology requiring excision of the tissue/region of interest. This is the most commonly used method in drug development studies to determine the drug distribution in the body or individual organ at a fixed point in time.…”

Section: Conventional Imaging Technologiesmentioning

confidence: 99%

“…out of all positronemitters employed by PET, 18 F-labeled pharmaceuticals have the most desirable properties: low positron energy and an optimal physical half-life of 110 min, which allows for more complex radiosynthesis and longer in vivo experiments and monitoring [22]. While MRI does not require a radioisotope, it can only detect isotopes with nuclear spins such as 1 H, 13 C, and 19 F. Because the sensitivity of MRI depends on the magnetic properties of the monitored nucleus and its natural abundance, drugs must typically contain 19 F or be enriched in 13 C in order to be effectively monitored in the body. Paramagnetic atoms such as gadolinium, iron, and manganese are utilized as contrast agents to increase the contrast in MRI images.…”

Section: Conventional Imaging Technologiesmentioning

confidence: 99%

Imaging Mass Spectrometry for Drugs and Metabolites

Oppenheimer

2013

Mass Spectrometry for Drug Discovery and Drug Development

View full text Add to dashboard Cite

Validation of 4-[18F]-ADAM as a SERT imaging agent using micro-PET and autoradiography

Cited by 39 publications

References 35 publications

Manipulation Therapy Prior to Diagnosis Induced Primary Osteosarcoma Metastasis—From Clinical to Basic Research

Manipulation Therapy Prior to Diagnosis Induced Primary Osteosarcoma Metastasis—From Clinical to Basic Research

Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson’s disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging

Imaging Mass Spectrometry for Drugs and Metabolites

Contact Info

Product

Resources

About